First Human Receives Experimental Therapy to Reverse Cellular Aging
GizmodoLife Biosciences, the biotech startup cofounded by Harvard geneticist David Sinclair, has dosed its first patient in an FDA-approved clinical trial using partial cellular reprogramming to reverse aging in the eye.
The experimental drug ER-100 uses three genetic factors to reset age-related epigenetic markers in retinal neurons, targeting glaucoma patients facing irreversible vision loss — the first time a reprogramming technology has ever been tested in humans.
If successful, the trial could open a new frontier in anti-aging medicine, with implications far beyond ophthalmology.